AU2020260479B2 — Methods and Compositions for the Specific Inhibition of Alpha-1 Antitrypsin by Double-Stranded RNA
Assigned to Novo Nordisk AS · Expires 2023-06-15 · 3y expired
What this patent protects
Figure 1 Ago2 cleavage sites aligned 1 9: 5'-UCUUCUUCU|CCCCAGUGAGCAUCGC-3' SEQ ID NO: 609 DsiRNA25/27mer 3'-AUAGAAGAAGA|GGGGUCACUGUAGC -5' SEQ ID NO: 213 siRNA 21mer 5'-UCUUCUUCU|CCCCAGUGAGCA-3'1 SEQ ID NO: 3323 3'-AUAGAAGAAGAGGGGUCACUC-5' SEQ ID NO: 3322 V DsiRNA 27127 5'…
USPTO Abstract
Figure 1 Ago2 cleavage sites aligned 1 9: 5'-UCUUCUUCU|CCCCAGUGAGCAUCGC-3' SEQ ID NO: 609 DsiRNA25/27mer 3'-AUAGAAGAAGA|GGGGUCACUGUAGC -5' SEQ ID NO: 213 siRNA 21mer 5'-UCUUCUUCU|CCCCAGUGAGCA-3'1 SEQ ID NO: 3323 3'-AUAGAAGAAGAGGGGUCACUC-5' SEQ ID NO: 3322 V DsiRNA 27127 5'-UAUCUUCUUCL'CCCCAGUGAGCAUCGC-3' SEQ ID NO: 1005 Blunt/Blunt 3 ' -AUAGAAGAAGACGGGGUCACUTUAGCG-5' SEQ ID NO: 213 siRNA 21mer 5'-UAUCUUCUUCUCCCCAGUGAG-3' SEQ ID NO: 807 Blunt-Blunt 3'-AUAGAAGAAGAGGGGUCAUC-5' SEQ ID NO: 3322 DsiRNA 27/27 5'-UAUCUUCUUCUCCCCAGUGAGCAUCAA-3' SEQ ID NO: 3324 Blunt/Fray-R 3 '-AUAGAAGAAGAIGGGGUCACUCGUAGCG-5' SEQ ID NO: 213 siRNA 21mer 5'-UAUCUUCUUCUCCCCAGUGCA-3' SEO ID NO: 3325 Blunt/Fray-R 3'-AUAGAAGAAGAGGGGUCACUC-5' SEQ ID NO: 3322 This invention relates to compounds, compositions, and methods useful for reducing a- 1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.